Osteoporosis is a common complication observed in rheumatoid arthritis (RA). Accelerated bone loss is always
a matter of concern. The pathogenesis of RA may be important for better understanding of the bone loss. The mechanism
involved in the bone loss in RA is not well understood although cytokines such as interleukin 1 and tumour necrosis factor
α (TNF α) have been strongly implicated. TNF α antagonists have revolutionised the treatment of RA in the recent years.
Beyond the control of disease activity in RA, accumulating evidence suggests that this form of therapy may provide beneficial
effects to the bone metabolism and remodeling. An extensive search of the literature was performed in the Medline,
Scopus and EBSCO databases to evaluate the documented research on the effects of TNF α antagonists in RA on bone
mineral density and bone turnover markers. The available data based on our systematic review, depict a significant association
between TNF α antagonists treatment and suppression of bone resorption.
Keywords: Bone mineral density, osteoporosis, rheumatoid arthritis, TNF α antagonists.
Rights & PermissionsPrintExport
Published on: 21 November, 2013
Page: [1552 - 1557]